L. Lopresti

Targeting Methyltransferases in Human Pathogenic Bacteria: Insights into Thymidylate Synthase (TS) and Flavin-Dependent TS (FDTS)

S. Mangani, C. Pozzi, G. Tassone, 2019, Molecules.

p66Shc Deficiency in Chronic Lymphocytic Leukemia Promotes Chemokine Receptor Expression Through the ROS-Dependent Inhibition of NF-κB

C. Baldari, L. Patrussi, L. Trentin, 2022, Frontiers in Oncology.

A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis.

S. Gemma, G. Campiani, S. Butini, 2021, Pharmacological research.

Evidence of Destabilization of the Human Thymidylate Synthase (hTS) Dimeric Structure Induced by the Interface Mutation Q62R

Maria Paola Costi, S. Mangani, C. Pozzi, 2019, Biomolecules.

Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents.

E. Novellino, M. Steinmetz, L. Altucci, 2019, European journal of medicinal chemistry.

A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients

S. Gemma, G. Campiani, S. Butini, 2024, Biomedicine & Pharmacotherapy.

Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy

C. Baldari, L. Patrussi, L. Lopresti, 2024, Frontiers in immunology.